Schizophrenia Market
Key Findings
- In the year 2021, the total prevalent cases of Schizophrenia were 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
- In 2021, the Schizophrenia market size was USD 8,664.6 million which is expected to rise by 2032.
- Some of the key companies in the Schizophrenia Market include Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
Request for sample pages to learn more about the market CAGR and trends Schizophrenia Market
DelveInsight's "Schizophrenia - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Schizophrenia market report provides current treatment practices, emerging drugs, Schizophrenia market share of the individual therapies, and current and forecasted Schizophrenia market size from 2019 to 2032 segmented by seven major markets. The report also covers current Schizophrenia treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Schizophrenia Understanding and Treatment Algorithm
The DelveInsight’s Schizophrenia epidemiology report gives a thorough understanding of Schizophrenia is a severe mental disorder in which people interpret reality abnormally. It may result in hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling. Contrary to public perception, schizophrenia is not a split or multiple personalities. Besides, it is not caused by childhood experiences, poor parenting, or lack of willpower, nor the symptoms are identical in each patient. In addition, the vast majority of people with schizophrenia are not violent and do not pose a danger to others.
In some people, schizophrenia appears suddenly and without warning. But for most, it comes on slowly, with subtle warning signs and a gradual decline in functioning long before the first severe episode. Often, friends or family members will know early on that something is wrong without knowing exactly what.
Scales measuring positive and negative symptoms in schizophrenia remain the primary mode of assessing and diagnosing schizophrenia by clinicians and researchers. The scales are mainly used to monitor the severity of positive and negative symptoms and track treatment responses in people with schizophrenia. Although these scales are widely used, the quality, as well as the general utility of each scale, varies. The quality is determined by the validity and reliability of the scales. The utility of the scale is determined by the time of administration and the settings for which the scales can be administered in research or clinical settings.
While no single physical or lab test can diagnose schizophrenia, a health care provider who evaluates the symptoms and the course of a person’s illness over 6 months can help ensure a correct diagnosis. The health care provider must rule out other factors such as brain tumors, possible medical conditions, and other psychiatric diagnoses, such as bipolar disorder. To be diagnosed with schizophrenia, a person must have two or more of the following symptoms occurring persistently in the context of reduced functioning: Delusions, Hallucinations, Disorganized speech, Disorganized or catatonic behavior, and Negative symptoms
Schizophrenia is a lifelong condition, but effective treatment can help a person manage the symptoms, prevent relapses, and avoid hospitalization. Schizophrenia requires lifelong treatment, even when symptoms have subsided. Treatment with medications and psychosocial therapy can help manage the condition; in some cases, hospitalization may be needed.
A psychiatrist experienced in treating schizophrenia usually guides treatment. The treatment team also may include a psychologist, social worker, psychiatric nurse, and possibly a case manager to coordinate care. The full-team approach may be available in clinics with expertise in schizophrenia treatment.
Schizophrenia requires a combination of treatments, including medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT).
Schizophrenia Epidemiology
The Schizophrenia epidemiology division provides insights about the historical and current Schizophrenia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the prevalent patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Schizophrenia epidemiology scenario in the 7MM covering the United States, the EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the Schizophrenia prevalent cases were found to be around 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted Schizophrenia epidemiology (segmented as Total Prevalent Cases of Schizophrenia, Total Diagnosed Cases of Schizophrenia, Gender-specific Cases of Schizophrenia, Severity-specific Cases of Schizophrenia, Age-specific Treated Cases of Schizophrenia, Total Treated Cases of Schizophrenia in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Schizophrenia Epidemiology
The epidemiology segment also provides the Schizophrenia epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- According to the DelveInsight, in the year 2021, the total prevalent cases of Schizophrenia were 2.97 million in the United States which are expected to grow during the study period, i.e., 2019–2032.
- The highest number of total prevalent cases of Schizophrenia among the EU5 countries was observed in Germany with 0.61 million cases in 2021 which are expected to grow during the study period, i.e., 2019–2032.
- In the year 2021, the total prevalent cases of Schizophrenia were 1.08 million cases in Japan which are expected to grow during the study period, i.e., 2019–2032.
Schizophrenia Drug Chapters
The drug chapter segment of the Schizophrenia report encloses the detailed analysis of Schizophrenia marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Schizophrenia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for Schizophrenia treatment.
Schizophrenia Market Outlook
With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and prevention of relapsed cases. Schizophrenia requires lifelong treatment, even when symptoms have subsided. Treatment with medications and psychosocial therapy can help manage the condition. In some cases, hospitalization may be needed. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat schizophrenia. For some patient groups, treatment strategies include a combination of neuroleptics and antiepileptics. Second-generation antipsychotic (SGAs) medications are generally preferred because they pose a lower risk of serious side effects than first-generation antipsychotics (FGAs). The FGAs have frequent and potentially significant neurological side effects, including the possibility of developing a movement disorder (tardive dyskinesia) that may or may not be reversible.
The treatment options for schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents to improve schizophrenia management and address the above-mentioned gaps.
According to DelveInsight, the Schizophrenia market in 7MM is expected to witness a major change in the study period 2019–2032.
Key Findings
The Schizophrenia market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Schizophrenia in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total Schizophrenia market size was USD 8,664.6 million which is expected to rise during the study period (2019–2032).
The United States Market Outlook
The total market size of Schizophrenia in the United States accounted for USD 5,203.7 million in 2021 which is expected to rise during the study period (2019–2032).
The EU5 Countries: Market Outlook
In the EU5, the total market size of Schizophrenia was USD 2,547.3 million in 2021, which is expected to rise during the study period (2019–2032).
Japan Market Outlook
In Japan, the total market size of Schizophrenia was USD 913.7 million in 2021, which is expected to rise during the study period (2019–2032).
Schizophrenia Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Schizophrenia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Schizophrenia Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Schizophrenia key players involved in developing targeted therapeutics.
Schizophrenia Pipeline Development Activities
The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for Schizophrenia emerging therapies.
Reimbursement Scenario in Schizophrenia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Schizophrenia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Schizophrenia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitively and Market Intelligence analysis of the Schizophrenia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Market Size |
USD 8,664.6 Million in 2021 |
|
Key Companies |
Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others |
Scope of the Report
- The report covers the descriptive overview of Schizophrenia, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Schizophrenia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Schizophrenia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Schizophrenia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Schizophrenia market.
Report Highlights
- In the coming years, the Schizophrenia market is set to change due to the upcoming therapies with novel mechanism of actions which are under investigation and ongoing research in the Schizophrenia; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Schizophrenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Schizophrenia. The launch of emerging therapies will significantly impact the Schizophrenia market.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Schizophrenia.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Schizophrenia Report Insights
- Patient Population
- Therapeutic Approaches
- Schizophrenia Pipeline Analysis
- Schizophrenia Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Schizophrenia Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Schizophrenia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Schizophrenia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights:
- What was the Schizophrenia drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Schizophrenia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest Schizophrenia market size during the forecast period (2019-2032)?
- At what CAGR, the Schizophrenia market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Schizophrenia market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Schizophrenia market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Schizophrenia?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Schizophrenia patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Schizophrenia in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Schizophrenia?
- Out of all 7MM countries, which country would have the highest prevalent population of Schizophrenia during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Schizophrenia treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Schizophrenia in the USA, Europe, and Japan?
- What are the Schizophrenia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Schizophrenia?
- How many therapies are in-development by each company for Schizophrenia treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Schizophrenia treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Schizophrenia therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Schizophrenia and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Schizophrenia?
- What are the global historical and forecasted markets of Schizophrenia?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Schizophrenia market
- To understand the future market competition in the Schizophrenia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Schizophrenia market
- To understand the future market competition in the Schizophrenia market
Frequently Asked Questions
1. Key Insights
2. Report Introduction
3. Schizophrenia Market Overview at a Glance
3.1. Market Share (%) Distribution of Schizophrenia in 2019
3.2. Market Share (%) Distribution of Schizophrenia in 2032
4. Executive Summary of Schizophrenia
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Early warning signs and symptoms of schizophrenia
6.3. Risk Factors of Schizophrenia
6.4. Subtypes of Schizophrenia
6.5. Mechanism of Schizophrenia
6.6. Genetics of Schizophrenia
6.7. Diagnosis
6.8. Symptoms Rating Scales in Schizophrenia
6.9. Differential Diagnosis
6.10. Algorithm for Differential Diagnosis of Negative Symptoms
6.11. Biomarkers in Schizophrenia
6.12. Treatment and Management
6.12.1. Acute-phase Symptoms
6.12.2. Medication (Antipsychotic)
6.12.3. Psychotherapy
6.12.4. Psychosocial therapy
6.12.5. ECT
6.12.6. Treatment algorithm
6.12.7. Treatment Guidelines
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Epidemiology Scenario in the 7MM
7.3.1. Total prevalent Cases of Schizophrenia in the 7MM
7.3.2. Total diagnosed Cases of Schizophrenia in the 7MM
7.3.3. Gender-specific cases of Schizophrenia in the 7MM
7.3.4. Severity-specific cases of Schizophrenia in the 7MM
7.3.5. Age-specific treated cases of Schizophrenia in the 7MM
7.3.6. Total Treated Cases of Schizophrenia in the 7MM
7.4. Epidemiology Scenario in the United States
7.4.1. Total prevalent Cases of Schizophrenia in the United States
7.4.2. Total diagnosed Cases of Schizophrenia in the United States
7.4.3. Gender-specific cases of Schizophrenia in the United States
7.4.4. Severity-specific cases of Schizophrenia in the United States
7.4.5. Age-specific treated cases of Schizophrenia in the United States
7.4.6. Total Treated Cases of Schizophrenia in the United States
7.5. Epidemiology Scenario in the EU5
7.5.1. Total Prevalent Cases of Schizophrenia in the EU5
7.5.2. Total Diagnosed Cases of Schizophrenia in the EU5
7.5.3. Gender-specific cases of Schizophrenia in the EU5
7.5.4. Severity-specific cases of Schizophrenia in the EU5
7.5.5. Age-specific treated cases of Schizophrenia in the EU5
7.5.6. Total Treated Cases of Schizophrenia in the EU5
7.6. Epidemiology Scenario in Japan
7.6.1. Total prevalent Cases of Schizophrenia in Japan
7.6.2. Total diagnosed Cases of Schizophrenia in the United States
7.6.3. Gender-specific cases of Schizophrenia in Japan
7.6.4. Severity-specific cases of Schizophrenia in Japan
7.6.5. Age-specific treated cases of Schizophrenia in Japan
7.6.6. Total Treated Cases of Schizophrenia in Japan
8. Patient Journey
9. Key Endpoints in Schizophrenia Clinical Trials
10. Marketed Therapies
10.1. REXULTI (brexpiprazole/OPC-34712): Otsuka America Pharmaceutical/Lundbeck
10.1.1. Drug description
10.1.2. Regulatory milestones
10.1.3. Other developmental activities
10.1.4. Pivotal clinical trial
10.1.5. Ongoing current pipeline activity
10.2. CAPLYTA (lumateperone/ITI-007): Intra-cellular Therapies
10.2.1. Drug description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Pivotal clinical trial
10.2.5. Ongoing current pipeline activity
10.3. LATUDA (lurasidone hydrochloride): Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma
10.3.1. Drug description
10.3.2. Regulatory milestones
10.3.3. Other developmental activities
10.3.4. Pivotal clinical trial
10.3.5. Ongoing current pipeline activity
10.4. SAPHRIS (asenapine): Merck/AbbVie/Schering-Plough Corporation/Allergan
10.4.1. Drug description
10.4.2. Regulatory milestones
10.4.3. Other developmental activities
10.4.4. Pivotal clinical trial
10.5. ABILIFY MYCITE (aripiprazole tablets with sensor): Otsuka Pharmaceutical
10.5.1. Drug description
10.5.2. Regulatory milestones
10.5.3. Other developmental activities
10.5.4. Pivotal clinical trial
10.6. VRAYLAR/REAGILA (cariprazine): Gedeon Richter/AbbVie
10.6.1. Drug description
10.6.2. Regulatory milestones
10.6.3. Other developmental activities
10.6.4. Pivotal clinical trial
10.6.5. Ongoing current pipeline activity
10.7. ADASUVE (loxapine): Alexza Pharmaceuticals
10.7.1. Drug description
10.7.2. Regulatory milestones
10.7.3. Other developmental activities
10.7.4. Pivotal clinical trial
10.8. SECUADO (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
10.8.1. Drug description
10.8.2. Regulatory milestones
10.8.3. Other developmental activities
10.8.4. Pivotal clinical trial
10.9. INVEGA SUSTENNA/INVEGA TRINZA/INVEGA HAFYERA (paliperidone palmitate): Janssen Pharmaceuticals
10.9.1. Drug description
10.9.2. Regulatory milestones
10.9.3. Other developmental activities
10.9.4. Pivotal clinical trial
10.10. ARISTADA and ARISTADA INITIO (aripiprazole lauroxil): Alkermes
10.10.1. Drug description
10.10.2. Regulatory milestones
10.10.3. Other developmental activities
10.10.4. Pivotal clinical trial
10.11. PERSERIS (risperidone): Indivior
10.11.1. Drug description
10.11.2. Regulatory milestones
10.11.3. Other developmental activities
10.11.4. Pivotal clinical trial
10.11.5. Ongoing current pipeline activity
10.12. LYBALVI (olanzapine and samidorphan): Alkermes
10.12.1. Drug description
10.12.2. Regulatory milestones
10.12.3. Other developmental activities
10.12.4. Pivotal clinical trial
10.12.5. Ongoing current pipeline activity
10.13. IGALMI (dexmedetomidine): BioXcel Therapeutics
10.13.1. Drug description
10.13.2. Regulatory milestones
10.13.3. Other developmental activities
10.13.4. Pivotal clinical trial
10.13.5. Ongoing current pipeline activity
10.14. RISPERDAL CONSTA (risperidone, long-acting): Alkermes/Janssen Pharmaceuticals
10.14.1. Drug description
10.14.2. Regulatory milestones
10.14.3. Other developmental activities
10.14.4. Pivotal clinical trial
10.15. ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck
10.15.1. Drug description
10.15.2. Regulatory milestones
10.15.3. Other developmental activities
10.15.4. Pivotal clinical trial
11. Emerging Therapies
11.1. ICLEPERTIN (BI-425809): Boehringer Ingelheim
11.1.1. Product description
11.1.2. Other developmental activities
11.1.3. Clinical developmental
11.1.4. Safety and efficacy
11.2. KarXT (Xanomeline-Trospium): Karuna Therapeutics
11.2.1. Product description
11.2.2. Other developmental activities
11.2.3. Clinical developmental
11.2.4. Safety and efficacy
11.3. NUPLAZID (pimavanserin): Acadia Pharmaceuticals
11.3.1. Product description
11.3.2. Other developmental activities
11.3.3. Clinical developmental
11.3.4. Safety and efficacy
11.4. Brilaroxazine (RP-5063): Reviva Pharmaceuticals
11.4.1. Product description
11.4.2. Other developmental activities
11.4.3. Clinical developmental
11.4.4. Safety and efficacy
11.5. ULOTARONT (SEP-363856): Sunivion/PsychoGenics/Otsuka Pharmaceuticals
11.5.1. Product description
11.5.2. Other developmental activities
11.5.3. Clinical developmental
11.5.4. Safety and efficacy
11.6. LUVADAXISTAT (NBI 1165844/TAK 831): Neurocrine Biosciences/Takeda
11.6.1. Product description
11.6.2. Other developmental activities
11.6.3. Clinical developmental
11.6.4. Safety and efficacy
11.7. Roluperidone (MIN-101): Minerva Neurosciences
11.7.1. Product Description
11.7.2. Other developmental activities
11.7.3. Clinical developmental
11.7.4. Safety and efficacy
11.8. Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
11.8.1. Other developmental activities
11.8.2. Clinical developmental
11.8.3. Safety and efficacy
11.9. LYN-005 (risperidone, weekly):- Lyndra Therapeutics
11.9.1. Product description
11.9.2. Other developmental activities
11.9.3. Clinical developmental
11.9.4. Safety and efficacy
11.10. OKEDI (risperidone ISM): Pharmaceuticals Laboratories
11.10.1. Product description
11.10.2. Regulatory milestone
11.10.3. Other developmental activities
11.10.4. Clinical developmental
11.10.5. Safety and efficacy
11.11. Emraclidine (CVL-231): Cerevel Therapeutics
11.11.1. Product description
11.11.2. Other developmental activities
11.11.3. Clinical developmental
11.11.4. Safety and efficacy
12. Conjoint Analysis
12.1. Attribute Analysis
12.2. Key Market Forecast Assumptions
13. Schizophrenia: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Market Size in the 7MM
13.3.1. Total Market Size of Schizophrenia in the 7MM
13.3.2. Market Size of Schizophrenia by Therapies in the 7MM
13.4. Market Size in the United States
13.4.1. Total Market Size of Schizophrenia in the United States
13.4.2. Market Size of Schizophrenia by Therapies in the United States
13.5. Market Size in the EU5
13.5.1. Total Market size of Schizophrenia in the EU5
13.5.2. Market Size of Schizophrenia by Therapies in EU5
13.6. Market Size in Japan
13.6.1. Total Market Size of Schizophrenia
13.6.2. Market size by Therapies of Schizophrenia
14. Market Access and Reimbursement
14.1. Patient Assistance Program
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Acronyms and Abbreviations
18.2. Bibliography
18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Table
Table 1: Summary of Schizophrenia, Market, Epidemiology, and Key Events (2019–2032)
Table 2: Early symptoms of schizophrenia
Table 3: Symptoms of Schizophrenia
Table 4: Clinical Features of Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Autism, and ADHD
Table 5: Second-generation Antipsychotic Drugs
Table 6: First-generation Antipsychotic Drugs
Table 7: Long-acting Injectable Antipsychotic
Table 8: Antipsychotic Medications: Available Oral and Short-acting Intramuscular Formulations and Dosing Considerations
Table 9: Long-acting Injectable Antipsychotic Medications: Dosing
Table 10: Total prevalent Cases of Schizophrenia in the 7MM (2019–2032)
Table 11: Total prevalent Cases of Schizophrenia in the 7MM (2019–2032)
Table 12: Severity-specific cases of schizophrenia in the 7MM (2019–2032)
Table 13: Age-specific diagnosed prevalence based on histological presentation in the 7MM (2019–2032)
Table 14: Total treated Cases of Schizophrenia in the 7MM (2019–2032)
Table 15: Total prevalent Cases of Schizophrenia in the United States (2019–2032)
Table 16: Total prevalent Cases of Schizophrenia in the United States (2019–2032)
Table 17: Severity-specific cases of schizophrenia in the United States (2019–2032)
Table 18: Age-specific diagnosed prevalence based on histological presentation in the 7MM (2019–2032)
Table 19: Total treated Cases of Schizophrenia in the United States (2019–2032)
Table 20: Total prevalent Cases of Schizophrenia in the EU5 (2019–2032)
Table 21: Total Diagnosed Cases of Schizophrenia in the EU5 (2019–2032)
Table 22: Severity-specific cases of schizophrenia in the EU5 (2019–2032)
Table 23: Age-specific treated cases of schizophrenia in the 7MM (2019–2032)
Table 24: Total Treated Cases of Schizophrenia in the EU5 (2019–2032)
Table 25: Total prevalent Cases of Schizophrenia in the United States (2019–2032)
Table 26: Total prevalent Cases of Schizophrenia in the United States (2019–2032)
Table 27: Severity-specific cases of schizophrenia in Japan (2019–2032)
Table 28: Age-specific treated cases of schizophrenia in Japan (2019–2032)
Table 29: Total treated Cases of Schizophrenia in Japan (2019–2032)
Table 30: REXULTI (brexpiprazole) Clinical Trial Description, 2022
Table 31: CAPLYTA (lumateperone), Clinical Trial Description, 2022
Table 32: LATUDA (lurasidone), Clinical Trial Description, 2022
Table 33: VRAYLAR (Cariprazine), Clinical Trial Description, 2022
Table 34: Risperidone, Clinical Trial Description, 2022
Table 35: LYBALVI (olanzapine + samidorphan), Clinical Trial Description, 2022
Table 36: IGALMI (dexmedetomidine), Clinical Trial Description, 2022
Table 37: Summary of Short-term Efficacy Pivotal trial
Table 38: ICLEPERTIN (BI-425809), Clinical Trial Description, 2022
Table 39: KarXT Clinical Trial Description, 2022
Table 40: NUPLAZID (pimavanserin), Clinical Trial Description, 2022
Table 41: Brilaroxazine (RP5063), Clinical Trial Description, 2022
Table 42: ULOTARONT (SEP-363856), Clinical Trial Description, 2022
Table 43: LUVADAXISTAT (NBI 1065844/TAK 831), Clinical Trial Description, 2022
Table 44: Roluperidone, Clinical Trial Description, 2022
Table 45: Evenamide, Clinical Trial Description, 2022
Table 46: ICELPERTIN (BI-425809), Clinical Trial Description, 2022
Table 47: Risperidone ISM Clinical Trial Description, 2022
Table 48: Emraclidine (CVL-231), Clinical Trial Description, 2022
Table 49: Key Market Forecast Assumptions for ZEGALOGUE (dasiglucagon)
Table 50: Key Market Forecast Assumptions for RZ358
Table 51: Key Market Forecast Assumptions for Avexitide
Table 52: Market Size of Schizophrenia in the 7MM, in USD Million (2019–2032)
Table 53: Total Market Size of Schizophrenia by Therapies in the 7MM, in USD Million (2019–2032)
Table 54: Market Size of Schizophrenia in the United States, in USD Million (2019–2032)
Table 55: Total Market Size of Schizophrenia by Therapies in the 7MM, in USD Million (2019–2032)
Table 56: Market Size of Schizophrenia in the EU5, in USD Million (2019–2032)
Table 57: Total Market Size of Schizophrenia by Therapies in the 7MM, in USD Million (2019–2032)
Table 58: Total Market Size of Schizophrenia in Japan, in USD Million (2019–2032)
Table 59: Total Market Size of Schizophrenia by Therapies in the 7MM, in USD Million (2019–2032)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Overview of Schizophrenia
Figure 3: Early Symptoms of Schizophrenia
Figure 4: Interaction of Genetic and Environmental Risk Factors in the Developmental Pathology of Schizophrenia
Figure 5: Neuron–glia Interactions in the Cerebral Cortex—Key Neural Substrates for the Pathology of Schizophrenia
Figure 6: Schematic Representation of Drug Actions that Normalize Aberrant Glutamate Neurotransmission in the Prefrontal Cortex of Schizophrenics
Figure 7: A Representative Molecular Pathway for Schizophrenia—Fine Tuning of the Glutamate Synapse
Figure 8: Differential Diagnosis of Negative Symptoms
Figure 9: Treatment Approaches f Schizophrenia
Figure 10: Types of Medications to Treat Schizophrenia
Figure 11: Types of Psychotherapy to Treat Schizophrenia
Figure 12: Treatment Algorithm of Schizophrenia
Figure 13: Total Prevalent Cases of Schizophrenia in the 7MM (2019–2032)
Figure 14: Total Diagnosed Cases of Schizophrenia in the 7MM (2019–2032)
Figure 15: Severity-specific cases of schizophrenia in the 7MM (2019–2032)
Figure 16: Age-specific cases of Schizophrenia in the 7MM (2019–2032)
Figure 17: Total Treated Cases of schizophrenia in the 7MM (2019–2032)
Figure 18: Total Prevalent Cases of Schizophrenia in the United States (2019–2032)
Figure 19: Total Diagnosed Cases of Schizophrenia in the United States (2019–2032)
Figure 20: Severity-specific cases of schizophrenia in the United States (2019–2032)
Figure 21: Age-specific cases of Schizophrenia in the United States (2019–2032)
Figure 22: Total Treated Cases of schizophrenia in the United States (2019–2032)
Figure 23: Total prevalent Cases of Schizophrenia in the EU5 (2019–2032)
Figure 24: Total Diagnosed Cases of Schizophrenia in the EU5 (2019–2032)
Figure 25: Severity-specific cases of schizophrenia in the EU5 (2019–2032)
Figure 26: Age-specific cases of Schizophrenia in the EU5 (2019–2032)
Figure 27: Total Treated Cases of schizophrenia in the EU5 (2019–2032)
Figure 28: Total Prevalent Cases of Schizophrenia in Japan (2019–2032)
Figure 29: Total Diagnosed Cases of Schizophrenia in Japan(2019–2032)
Figure 30: Severity-specific cases of schizophrenia in Japan (2019–2032)
Figure 31: Age-specific treated cases of Schizophrenia in Japan (2019–2032)
Figure 32: Total Treated Cases of schizophrenia in Japan (2019–2032)
Figure 33: Total Market Size of Schizophrenia in the 7MM, USD Million (2019–2032)
Figure 34: Total Market Size of Schizophrenia by Therapies in the 7MM, in USD Million (2019–2032)
Figure 35: Market Size of Schizophrenia in the United States, USD Million (2019–2032)
Figure 36: Market Size of Schizophrenia by Therapies in the United States, in USD Million (2019–2032)
Figure 37: Total Market Size of Schizophrenia in the EU5, USD Million (2019–2032)
Figure 38: Total Market Size of Schizophrenia by Therapies in EU5, in USD Million (2019–2032)
Figure 39: Total Market Size of Schizophrenia in Japan, in USD Million (2019–2032)
Figure 40: Total Market Size of Schizophrenia by Therapies in Japan, in USD Million (2019–2032)
Boehringer Ingelheim
Karuna Therapeutics
Acadia Pharmaceuticals
Reviva Pharmaceuticals
Sunivion/PsychoGenics/Otsuka Pharmaceuticals
Neurocrine Biosciences/Takeda
Minerva Neurosciences
Newron Pharmaceuticals
Lyndra Therapeutics
Pharmaceuticals Laboratories
Cerevel Therapeutics